BACKGROUND: Medical treatment of type 2 diabetes has often insufficient clinical results at long term. Although the surgical option is a well-established alternative for obese patients, the procedures in non-obese are currently being developed. METHODS: A 12-month prospective trial with ten diabetic non-obese patients who underwent laparoscopic sleeve gastrectomy with duodenojejunal bypass is presented. Changes in fasting blood glucose, HbA1c, weight, and BMI were determined. RESULTS: There was a significant reduction in fasting glycemia and HbA1c at 1 year postoperative (p < 0.004). One patient had an intra-abdominal bleeding and a wound infection treated with blood transfusion and antibiotic therapy, respectively. The BMI decreased 12.1% and in any case it was reduced to less than 20 kg/m². CONCLUSIONS: Laparoscopic sleeve gastrectomy with duodenojejunal bypass is a promising procedure for the treatment of non-obese patients with type 2 diabetes. Studies with large number of patients and longer follow-up are necessary to make definitive conclusions.
BACKGROUND: Medical treatment of type 2 diabetes has often insufficient clinical results at long term. Although the surgical option is a well-established alternative for obesepatients, the procedures in non-obese are currently being developed. METHODS: A 12-month prospective trial with ten diabetic non-obesepatients who underwent laparoscopic sleeve gastrectomy with duodenojejunal bypass is presented. Changes in fasting blood glucose, HbA1c, weight, and BMI were determined. RESULTS: There was a significant reduction in fasting glycemia and HbA1c at 1 year postoperative (p < 0.004). One patient had an intra-abdominal bleeding and a wound infection treated with blood transfusion and antibiotic therapy, respectively. The BMI decreased 12.1% and in any case it was reduced to less than 20 kg/m². CONCLUSIONS: Laparoscopic sleeve gastrectomy with duodenojejunal bypass is a promising procedure for the treatment of non-obesepatients with type 2 diabetes. Studies with large number of patients and longer follow-up are necessary to make definitive conclusions.
Authors: J Vidal; A Ibarzabal; J Nicolau; M Vidov; S Delgado; G Martinez; J Balust; R Morinigo; A Lacy Journal: Obes Surg Date: 2007-08 Impact factor: 4.129
Authors: Francesco Rubino; Antonello Forgione; David E Cummings; Michel Vix; Donatella Gnuli; Geltrude Mingrone; Marco Castagneto; Jacques Marescaux Journal: Ann Surg Date: 2006-11 Impact factor: 12.969
Authors: Almino C Ramos; Manoel P Galvão Neto; Yglésio Moyses de Souza; Manoela Galvão; Abel H Murakami; Andrey C Silva; Edwin G Canseco; Raúl Santamaría; Trino A Zambrano Journal: Obes Surg Date: 2008-11-06 Impact factor: 4.129
Authors: Francesco Rubino; Michel Gagner; Paolo Gentileschi; Subhash Kini; Shoji Fukuyama; John Feng; Ed Diamond Journal: Ann Surg Date: 2004-08 Impact factor: 12.969
Authors: Carel W le Roux; Simon J B Aylwin; Rachel L Batterham; Cynthia M Borg; Frances Coyle; Vyas Prasad; Sandra Shurey; Mohammad A Ghatei; Ameet G Patel; Stephen R Bloom Journal: Ann Surg Date: 2006-01 Impact factor: 12.969